Scales in Parkinson's disease (Journal of Neurology (2006) 253, Suppl. 4, (IV/32-IV/35) DOI: 10.1007/s00415-006-4008-0);Scales in Parkinson's disease

Journal of Neurology

Volumn 253, Issue SUPPL. 4, 2006, Pages 1444-

  Ebersbach, Georg ^a   Baas, Horst ^b   Csoti, Ilona ^c   Müngersdorf, Martina ^d   Deuschl, Günther ^e  

^a Kliniken Beelitz GmbH Neurologisches Fachkrankenhaus für Bewegungsstörungen Parkinson   (Germany)

^b Klinikum Stadt Hanou   (Germany)

^c Gertrudis Klinik   (Germany)

^d Christian Albrechts Universität ^*

^e UNIVERSITY OF KIEL   (Germany)

Author keywords

ICF; Parkinson's disease; Quality of life; Scales; UPDRS

Indexed keywords

BECK DEPRESSION INVENTORY; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DEMENTIA; DISABILITY; HAMILTON SCALE; HEALTH STATUS; HUMAN; MINI MENTAL STATE EXAMINATION; NEUROPSYCHIATRY; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCREENING; SOCIAL STATUS; SYMPTOMATOLOGY;

EID: 33748298910     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-0082-9     Document Type: Erratum

References (20)

1. Chaudhuri KR, Martinez-Matín P, Schapira AHV et al. (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. Mov Disord 21:916-923
2. Fahn S, Elton RL (1987) UPDRS program members Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson's disease, vol. 2, Macmillanm Healthcare Information, Florham Park, pp 153-163
3. Friedberg G, Zoldan J, Weizman A, Melamed E (1998) Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 21:280-284
4. Goetz CG, Stebbins GT, Chmura Ta, et al. (1995) Teaching tape for the motor section of the Unified Parkinson's Disease Rating Scale. Mov Disord 10:263-266
5. Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D (2005) An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 112(2):221-230
6. Korczyn AD, Brunt ER, Larsen JP, et al. (1999) A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease: the 053 Study Group. Neurology 53:364-370
7. Marras C, Lang A, Krahn M, et al. (2004) Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 19:22-28
8. Mitchell SL, Harper DW, Bhalla R (2000) Patterns of outcome measurements in Parkinson's disease clinical trials. Neuroepidemiology 19:100-108
9. Miyasaki JM, Shannon K, Voon V, et al. (2006) Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:996-1002
10. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease (2003) The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations. Mov Disord 18:738-750
11. Peto V, Jenkinson C (1999) Quality of life measures in Parkinson's disease. In: Martín PM, Koller WC (eds) Quality of life in Parkinson's disease. Masson S. A., Barcelona, pp 37-54
12. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002) Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled doubleblind study in Germany and Austria (Celomen study). Acta Neurol Scand 105(4):245-255
13. Ramaker C, Marinus J, Stiggelbout, et al. (2002) Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord 17:867-876
14. Rascol O, Brooks DJ, Brunt ER, et al. (1998) Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopacontrolled study - 056 Study Group. Mov Disord 13:39-45
15. Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K (2005) Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 111(1):21-28
16. Richards M, Marder K, Cote L, et al. (1994) Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord 9:89-91
17. Schrag A, Jahanshahi M, Quinn N (2000) What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 69(3):308-312
18. Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15(6):1112-1118
19. Schrag A, Sampaio C, Counsell N, Poewe W (2006) Minimal clinically important change of the Unified Parkinson's Disease Rating Scale. Mov Disord, (in press) DOI 10.1002/mds.20914
20. World Health Organization (2002) Towards a Common Language for Function Disability and Health. Geneva. www.who.int/icf